obamegine profile

obamegine: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	441064
CHEMBL ID	452895
CHEBI ID	7714
MeSH ID	M0106974

Synonym
obamegin
nsc-123123
15,30-diaza-20,25-dimethoxy-15,30-dimethyl-7,23-dioxaheptacyclo[22.6.2.2<3,6>.1<8,12>.1<14,18>.0<22,36>.0<27,31>]hexatriaconta-3(33),4,6(34),8,10,12(35),18(36),19,21,24,26,31-dodecaene-9,21-diol
stepholine
C06513
(+)-obamegine
479-37-8
obamegine
nsc-251534
CHEMBL452895
chebi:7714 ,
nsc 123123
unii-75k1ei2hdp
berbaman-7,12-diol, 6,6'-dimethoxy-2,2'-dimethyl-
75k1ei2hdp ,
16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinoline-12,22-diol, 3,4,4a,5,16a,17,18,19-octahydro-21,26-dimethoxy-4,17-dimethyl-, (4as-(4ar,16as))-
obamegine, (+)-
16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinoline-12,22-diol, 3,4,4a,5,16a,17,18,19-octahydro-21,26-dimethoxy-4,17-dimethyl-, (4as,16ar)-
bdbm50508726
obamogenine
Q27107564
DTXSID301098623
(4as,16ar)-3,4,4a,5,16a,17,18,19-octahydro-21,26-dimethoxy-4,17-dimethyl-16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido[2',3':17,18][1,11]dioxacycloeicosino[2,3,4-ij]isoquinoline-12,22-diol

Excerpt	Relevance	Reference
" Increasing concentrations of thalistyline produced parallel shifts to the right in the dose-response curves of phenylephrine."	( A pharmacological study of two bisbenzylisoquinoline alkaloids, thalistyline and obamegine. Banning, JW; Patil, PN; Salman, KN, )	0.36

Class	Description
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
bisbenzylisoquinoline alkaloid	A type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cholinesterase	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	1.5599	10.0000	AID1537270
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	97.0000	0.0000	0.9332	10.0000	AID1537269
Prolyl endopeptidase	Homo sapiens (human)	IC50 (µMol)	200.0000	0.0011	1.9896	9.7500	AID1537274
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cholinesterase	Homo sapiens (human)
learning	Cholinesterase	Homo sapiens (human)
negative regulation of cell population proliferation	Cholinesterase	Homo sapiens (human)
neuroblast differentiation	Cholinesterase	Homo sapiens (human)
peptide hormone processing	Cholinesterase	Homo sapiens (human)
response to alkaloid	Cholinesterase	Homo sapiens (human)
cocaine metabolic process	Cholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission	Cholinesterase	Homo sapiens (human)
response to glucocorticoid	Cholinesterase	Homo sapiens (human)
response to folic acid	Cholinesterase	Homo sapiens (human)
choline metabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
proteolysis	Prolyl endopeptidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amyloid-beta binding	Cholinesterase	Homo sapiens (human)
catalytic activity	Cholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Cholinesterase	Homo sapiens (human)
cholinesterase activity	Cholinesterase	Homo sapiens (human)
protein binding	Cholinesterase	Homo sapiens (human)
hydrolase activity, acting on ester bonds	Cholinesterase	Homo sapiens (human)
enzyme binding	Cholinesterase	Homo sapiens (human)
choline binding	Cholinesterase	Homo sapiens (human)
identical protein binding	Cholinesterase	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
serine-type endopeptidase activity	Prolyl endopeptidase	Homo sapiens (human)
protein binding	Prolyl endopeptidase	Homo sapiens (human)
serine-type peptidase activity	Prolyl endopeptidase	Homo sapiens (human)
oligopeptidase activity	Prolyl endopeptidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Cholinesterase	Homo sapiens (human)
nuclear envelope lumen	Cholinesterase	Homo sapiens (human)
endoplasmic reticulum lumen	Cholinesterase	Homo sapiens (human)
blood microparticle	Cholinesterase	Homo sapiens (human)
plasma membrane	Cholinesterase	Homo sapiens (human)
extracellular space	Cholinesterase	Homo sapiens (human)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
nucleus	Prolyl endopeptidase	Homo sapiens (human)
cytoplasm	Prolyl endopeptidase	Homo sapiens (human)
cytosol	Prolyl endopeptidase	Homo sapiens (human)
membrane	Prolyl endopeptidase	Homo sapiens (human)
cytosol	Prolyl endopeptidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay ID	Title	Year	Journal	Article
AID1537270	Inhibition of human BuChE using butyrylthiocholine iodide as substrate measured for 1 min by Ellman's method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID399500	Toxicity in dog at 0.5 to 4 mg/kg, iv
AID377947	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs	1999	Journal of natural products, Jan, Volume: 62, Issue:1	Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID1537277	Permeability of the compound after 2.45 hrs by PAMPA	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID399502	Cardiovascular effect in anesthetized normotensive iv dosed dog assessed as decrease in heart rate
AID1537276	Inhibition of GSK3B (unknown origin) at 10 uM relative to control	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID377948	Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum W2	1999	Journal of natural products, Jan, Volume: 62, Issue:1	Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID377946	Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6	1999	Journal of natural products, Jan, Volume: 62, Issue:1	Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID399497	Antagonist activity at alpha adrenergic receptor in rabbit aortic strips assessed as decrease in of phenylephrine-induced contraction at 3 X 10'-4 M
AID399501	Cardiovascular effect in anesthetized normotensive iv dosed dog assessed as decrease in mean arterial pressure
AID674584	Cytotoxicity against human U937 cells assessed as cell growth at 12 uM after 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID674579	Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID377944	Cytotoxicity against human KB cells after 72 hrs by SRB assay	1999	Journal of natural products, Jan, Volume: 62, Issue:1	Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID399498	Antagonist activity at alpha adrenergic receptor in rabbit aortic strips assessed as inhibition of phenylephrine-induced contraction
AID399505	Cardiovascular effect in anesthetized normotensive dog assessed as reduction in mean arterial pressure at 2 mg/kg, iv dosed twice with second dose being administered 2.5 hrs interval after the first dose
AID674577	Induction of rat C/EBPalpha expression transfected in human U937 cells at 12 uM after 24 hrs by luciferase reporter gene assay relative to ATRA	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID377945	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs	1999	Journal of natural products, Jan, Volume: 62, Issue:1	Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID399496	Antagonist activity at alpha adrenergic receptor in rabbit aortic strips assessed as decrease in of phenylephrine-induced contraction at 10'-4 M
AID399799	Blockade of neuromuscular transmission activity in albino Sprague-Dawley rat hemidiaphragm assessed as inhibition of electrically-stimulated phrenic nerve contraction at 1 to 30 X 10'-6 M
AID1537274	Inhibition of POP (unknown origin) using (Z)-Gly-Pro-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by spectrophotometric method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID399503	Toxicity in iv dosed dog assessed as inhibition of respiration
AID397125	Antimalarial activity against Plasmodium falciparum
AID1537271	Selectivity index, ratio of IC50 for human BuChE to IC50 for human AChE	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID674572	Induction of rat C/EBPalpha expression transfected in human U937 cells after 24 hrs by luciferase reporter gene assay relative to ATRA	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID399504	Cardiovascular effect in anesthetized normotensive dog assessed as decrease in mean arterial pressure at 2 mg/kg, iv upto 22 mins
AID1537269	Inhibition of human AChE using acetylthiocholine iodide as substrate measured for 1 min by Ellman's method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
berberine [no description available]	2.21	1	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	2	1	organofluorine compound; piperidines; quinolines; secondary alcohol
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.31	1	pyrrole; secondary amine
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	2.21	1	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
cepharanthine cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.	2.43	2	bisbenzylisoquinoline alkaloid; isoquinolines
jkl 1073a 8-oxoberberine: structure given in first source	2.21	1
laudanosine laudanosine: opium alkaloid	2.07	1	isoquinolines
palmatine burasaine: structure in first source	2.21	1	berberine alkaloid; organic heterotetracyclic compound	plant metabolite
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	2.43	2	bisbenzylisoquinoline alkaloid; isoquinolines
fangchinoline [no description available]	2.43	2	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
fangchinoline fangchinoline: RN given refers to parent cpd; limacine is the (1'beta)-isomer; 7-O-demethyltetrandrine is the (1S,1'S)-isomer. fangchinoline : A bisbenzylisoquinoline alkaloid that is (1beta)- berbaman which has been substituted by methyl groups at the 2 and 2' positions, by methoxy groups at the 6, 6', and 12 positions, and by a hydroxy group at position 7. Isolated from Stephania tetrandra, it has been found to possess neuroprotective and anti-tumour activity.	2	1
n-benzyloxycarbonylprolylprolinal N-benzyloxycarbonylprolylprolinal: inhibitor of prolyl endopeptidase	2.21	1
coclaurine coclaurine: RN given refers to (S)-isomer; structure. (S)-coclaurine : The (S)-enantiomer of coclaurine.	2.31	1	coclaurine
trilobine trilobine: RN given refers to parent cpd	2	1	isoquinolines
chondocurine (1beta)-(+-)-isomer curine: structure in first source	2.31	1	aromatic ether
berbamine [no description available]	2.75	3	bisbenzylisoquinoline alkaloid; isoquinolines
aromoline aromoline: from roots of Stephania cepharantha; structure given in first source	2.72	3
oxyacanthine oxyacanthine: a putative calcium channel blocker; structure in first source. oxyacanthine : A macrocycle that is oxyacanthan that is substituted by methoxy groups at positions 6, 6', and 7, methyl groups at positions 2 and 2', and a hydroxy group at the 12' position.	2.07	1	bisbenzylisoquinoline alkaloid; isoquinolines; macrocycle; phenols; tertiary amino compound
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.07	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
isotetrandrine [no description available]	2	1
huperzine a [no description available]	2.21	1	organic heterotricyclic compound; primary amino compound; pyridone; sesquiterpene alkaloid	EC 3.1.1.7 (acetylcholinesterase) inhibitor; neuroprotective agent; nootropic agent; plant metabolite
quinine [no description available]	2	1	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic

Condition	Indicated	Relationship Strength	Studies	Trials
Acute Confusional Senile Dementia [description not available]	0	2.21	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.21	1	0

obamegine

Description

Cross-References

Synonyms (23)

Research Excerpts

Dosage Studied

Drug Classes (2)

Protein Targets (3)

Inhibition Measurements

Biological Processes (26)

Molecular Functions (18)

Ceullar Components (18)

Bioassays (26)

Research

Studies (5)

Study Types

obamegine

Description

Cross-References

Synonyms (23)

Research Excerpts

Dosage Studied

Drug Classes (2)

Protein Targets (3)

Inhibition Measurements

Biological Processes (26)

Molecular Functions (18)

Ceullar Components (18)

Bioassays (26)

Research

Studies (5)

Study Types

Related Drugs (23)

Related Conditions (2)